Benefits
Mast Cell Stabilization
Luteolin is a potent inhibitor of mast cell degranulation — mast cells release histamine, tryptase, and inflammatory mediators in allergies and mast cell activation syndrome (MCAS). Theoharides 2015 and others establish luteolin as foundational MCAS supplement. Often combined with quercetin.
Neuroinflammation Reduction
Microglial activation drives neuroinflammation in Alzheimer's, autism, and chronic neurological conditions. Luteolin reduces microglial activation and pro-inflammatory cytokines in animal models. Theoretical autism spectrum applications.
Cancer Chemoprevention Research
Extensive in vitro evidence: induces apoptosis, inhibits angiogenesis, reduces metastasis in cancer cell lines. Animal models show tumor growth reduction. Human clinical translation limited.
Cardiovascular Anti-Atherosclerotic Effects
Reduces LDL oxidation, vascular inflammation, and adhesion molecule expression — anti-atherosclerotic mechanisms. Modest cholesterol effects. Mostly mechanistic and animal evidence.
Senolytic Activity (Adjunctive)
Identified along with fisetin in Mayo Clinic flavonoid screening as having senolytic activity, though less potent than fisetin. Component of multi-flavonoid longevity stacks.
Mechanism of action
Mast Cell Stabilization
Luteolin inhibits mast cell degranulation by stabilizing mast cell membranes and inhibiting calcium-dependent degranulation pathways. Reduces histamine, tryptase, and cytokine release. Foundational mechanism for allergy/MCAS application.
NF-κB Pathway Inhibition
Inhibits NF-κB activation — reducing pro-inflammatory gene expression (TNF-alpha, IL-6, IL-1β, COX-2, iNOS). Broad anti-inflammatory profile.
Microglial Modulation (Brain)
Reduces activated microglia (the brain's immune cells) — relevant for neuroinflammation in chronic neurological conditions. Crosses blood-brain barrier.
Histamine N-Methyltransferase Effects
Modest inhibition of histamine breakdown enzymes balanced against mast cell stabilization — net effect depends on context. Generally anti-allergic clinically.
Clinical trials
Open-label trial of luteolin formulation (with quercetin and rutin in liposomal form) in children with ASD over 26 weeks.
37 children with ASD.
Open-label improvements in adaptive behaviors, communication, social interaction, and GI symptoms. CRITICAL CAVEAT: open-label, no placebo control; subsequent placebo-controlled trials less robust. Theoretical mechanism (neuroinflammation reduction) has gained interest.
Multiple papers and case series by Theoharides et al. on luteolin as mast cell stabilizer for MCAS, chronic urticaria, related conditions.
MCAS patients, chronic urticaria patients.
Modest symptom improvements in mast cell-related conditions. Open-label/observational primarily; rigorous RCTs limited. Foundational supplement in functional medicine MCAS protocols.
About this ingredient
Luteolin (3',4',5,7-tetrahydroxyflavone) is a FLAVONE — distinguished from flavonols (like quercetin) by lack of 3-hydroxyl group on flavone backbone. Found abundantly in PARSLEY, celery, artichoke, broccoli, peppers, oregano, thyme, sage, basil, peppermint, rosemary, and chamomile. Particularly concentrated in CELERY SEEDS and ARTICHOKE LEAVES.
KEY FUNCTIONAL POSITIONING: luteolin is foundational in MAST CELL ACTIVATION SYNDROME (MCAS) protocols developed by Theoharides and colleagues — combined with quercetin as primary mast cell stabilization supplements. Also important in neuroinflammation research.
EVIDENCE-BASED USES: (1) MAST CELL ACTIVATION SYNDROME (MCAS) — foundational; clinical use validated by Theoharides research; (2) ALLERGIC RHINITIS, chronic urticaria — anti-histamine/mast cell mechanism; (3) NEUROINFLAMMATION — microglial modulation; theoretical autism spectrum applications (Theoharides 2012 — open-label only); (4) Cardiovascular — anti-atherosclerotic mechanisms; (5) Senolytic adjunct (less potent than fisetin); (6) Cancer chemoprevention research.
CRITICAL CAUTIONS: (1) MCAS COMPLEX MANAGEMENT — luteolin is one component of multi-pronged MCAS approach; trigger avoidance, antihistamines (H1+H2), mast cell stabilizers (cromolyn), low-histamine diet, and addressing underlying causes (mold, infections, hormonal) all relevant; consult MCAS-knowledgeable provider; (2) AUTISM CLAIMS — based largely on open-label data and theoretical neuroinflammation rationale; placebo-controlled evidence weaker; should not replace evidence-based ASD interventions; consult pediatrician/specialist; (3) PREGNANCY/LACTATION — limited safety data at supplemental doses; AVOID supplementation; dietary luteolin from food likely safe; (4) BIOAVAILABILITY — oral luteolin bioavailability low; LIPOSOMAL formulations (e.g., PureLut™, NeuroProtek®) substantially improve absorption and are preferred for therapeutic doses; (5) THYROID — theoretical thyroid peroxidase inhibition at very high doses; relevant for those with thyroid conditions; (6) DOSE — 100-300 mg/day general; 200-500 mg/day in MCAS protocols; liposomal forms allow lower doses; (7) DRUG INTERACTIONS — anticoagulants (theoretical), CYP interactions; (8) PRE-SURGERY — discontinue 1-2 weeks before; (9) THEOHARIDES BRANDS — NeuroProtek® (luteolin + rutin + quercetin) is widely-cited combination product; not the only option; generic luteolin works; (10) Combined with QUERCETIN, RUTIN, and other flavonoids in MCAS protocols — synergistic effects; (11) For GENERAL anti-inflammatory/antioxidant use, DIETARY luteolin from celery, parsley, artichoke, herbs is the foundational approach; supplementation for therapeutic indications (MCAS, neuroinflammation).